Dengue infection in kidney transplant recipients: clinical course and its impact on renal function

Infecção por dengue em receptores de transplante renal: curso clínico e seu impacto na função renal

Introduction: Kidney transplant recipients (KTR) are at increased risk for dengue virus (DENV) infection. The aim of this study was to outline the clinical presentation and laboratory profile of DENV infection in KTR and its impact on renal function.

Methods: This was a retrospective study of KTR diagnosed with DENV infection. Adult patients who visited Santa Casa de Belo Horizonte Nephrology Center between April and September 2019 were included. Patients who did not sign the Informed Consent were excluded. Data were collected from the database and medical records. The study was approved by the local Institutional Ethics Committee and the Informed Consent was obtained.

Results: Nineteen KTR were evaluated. The main signs and symptoms were myalgia, headache/retro-orbital pain, fever, and gastrointestinal symptoms. Two patients had acute cholecystitis without calculus, three experienced pleural and/or pericardial effusion, and one developed acute myocarditis. All patients were under immunosuppression with prednisone, tacrolimus, and mycophenolate, and most were not receiving induction therapy. Temporary suspension/reduction of immunosuppression was required in 58% of patients and leukopenia was the most common reason. Thrombocytopenia was common and 58% of patients developed acute kidney injury. All patients recovered renal function.

Conclusions: DENV infection in KTR patients seems to follow a similar course as in the general population. Although there was no control group, we suspect that immunosuppression, preexisting kidney disease or type of donor was not a determining factor in most patients. Transient renal dysfunction was common but reversible. No patient experienced death or graft loss.

Keywords: Dengue Virus; Kidney Transplantation; Immunosuppression; Primary Graft Dysfunction.

Resumo

Introdução: Receptores de transplante renal (RTR) apresentam maior risco de infecção pelo vírus da dengue (DENV). O objetivo deste estudo foi delinear apresentação clínica e perfil laboratorial da infecção por DENV em RTR e seu impacto na função renal.

Métodos: Este foi um estudo retrospectivo de RTR diagnosticados com infecção por DENV. Incluiu-se pacientes adultos que estiveram no Centro Nefrológico da Santa Casa de Belo Horizonte entre Abril/Setembro, 2019. Foram excluídos pacientes que não assinaram o Termo de Consentimento Livre e Esclarecido. Dados foram coletados do banco de dados e registros médicos. O estudo foi aprovado pelo Comitê de Ética Institucional local e obteve-se o Consentimento Livre e Esclarecido.

Resultados: Avaliou-se dezenove RTR. Principais sinais e sintomas foram myalgia, cabeça/retro-orbital, febre, e sintomas gastrointestinais. Dois pacientes apresentaram colecistite aguda sem cálculo, três sofreram derrame pleural e/ou pericárdico, um desenvolveu miocardite aguda. Todos os pacientes estavam sob imunossupressão com prednisona, tacrolimus, e micofenolato. A maioria não estava recebendo terapia de indução. Suspensão/redução temporária da imunossupressão foi necessária em 58% dos pacientes e leucopenia foi a razão mais comum. Trombocitopenia foi comum e 58% dos pacientes desenvolveram lesão renal aguda. Todos recuperaram a função renal.

Conclusões: A infecção por DENV em pacientes RTR parece seguir um curso semelhante ao da população em geral. Embora não houvesse grupo controle, suspeitamos que imunossupressão, doença renal preexistente ou tipo de doador não foram fator determinante na maioria dos pacientes. Disfunção renal transitória foi comum, mas reversível. Nenhum paciente veio ao óbito ou sofreu perda do enxerto.

Descritores: Vírus da dengue; Transplante de Rim; Imunossupressão; Disfunção Primária do Enxerto.
**INTRODUCTION**

Dengue virus (DENV) infection is an arthropod-borne disease caused by an RNA virus of the Flaviviridae family that is transmitted primarily by the mosquito *Aedes aegypti*. There are four serologically distinct dengue viruses: DENV-1, DENV-2, DENV-3 and DENV-4. Infection with one serotype does not confer immunity to other serotypes. DENV infection can occur as an endemic disease or as epidemic outbreaks. It is endemic in many tropical and subtropical countries, such as Brazil, the Caribbean, and Southeast Asian countries, and causes an enormous economic burden, especially for the health sector. Furthermore, rapid urbanization with overpopulation in tropical and subtropical countries favors the association of dengue epidemics and major lifestyle changes with the onset of diabetes, high blood pressure and, consequently, chronic kidney disease (CKD).

Annually, approximately 390 million people become infected with DENV, and 3.9 million live in countries where it is endemic. According to the Brazilian Ministry of Health (BMH), 971,136 dengue cases were registered from January to November 2020, with an incidence rate of 462.1 cases per 100 thousand population and 528 deaths in the country.

The illness can be asymptomatic or symptomatic, and common symptoms are fever, myalgia, arthralgia, headache, skin rash, and retro-orbital pain. It can cause a systemic and dynamic disease that varies from mild to severe form and may lead to death. Dengue can be divided into two main categories: undifferentiated dengue (with or without warning signs) and severe dengue. This classification of dengue fever was designed to help healthcare workers and minimize the risk of contracting severe dengue fever. Recently, there has been an increase in kidney transplants in Brazil. Kidney transplant recipients (KTR) living in endemic areas are at higher risk of DENV infection, and this vulnerable group of immunosuppressed patients can develop a more severe disease. However, previous studies suggest that dengue fever is mild in KTR and the disease does not affect allograft function. Although severe morbidity (graft failure that needs dialysis and graft nephrectomy) and mortality had been reported, severe dengue infection is thought to be due to immune-mediated mechanisms and may not occur in transplant recipients who have a muted immune response.

Unfortunately, there are few studies that address this issue in the literature. The aim of this study was to outline the clinical presentation and laboratory profile of DENV infection in KTR and the impact of the disease on kidney function.

**MATERIALS AND METHODS**

**STUDY DESIGN**

This was a retrospective study of KTR that were diagnosed with DENV infection.

**PATIENTS**

Adult KTR diagnosed with DENV infection confirmed by laboratory test at Santa Casa de Belo Horizonte Nephrology Center from April to September 2019 were included. This hospital has a comprehensive kidney transplant program where patients receive free transplant surgery and medications for life. Patients are followed up regularly and referred for evaluation in the event of graft dysfunction or serious illness. Patients who do not signed the Informed consent were excluded.

**METHODS**

Data were collected from the database of the Santa Casa de Belo Horizonte Nephrology Center, where patient data are registered, and from patients’ medical records. The variables collected were: demographic and clinical data (sex, age, length of hospital stay, dengue signs and symptoms and clinical stage), transplant data (donor type, immunosuppression, induction), and laboratory data (serological diagnosis, biochemical kidney tests, blood tests, kidney function test). The CKD-EPI formula was used for the glomerular filtration rate calculation.

A dengue case was defined according to BMH 2016, Center for Disease Control and Prevention (CDC) 2015 and World Health Organization (WHO) 2009 as: a compatible clinical disease with either positive serology (IgM dengue antibody) and/or positive NS1 antigen, during the study period.

Dengue patients were classified in Group A - dengue without warning signs, no special condition, no social risk, and no comorbidities; Group B - dengue without warning signs, with special condition, or with social risk and comorbidity; Group C - dengue with warning signs and no severe signs: severe abdominal pain (referred to or on palpation) and continuous, persistent vomiting, fluid accumulation (ascites, pleural effusion, pericardial effusion), postural hypotension and/or lipothymia, hepatomegaly greater than five centimeters, and/or coagulation abnormalities. Group D - dengue with warning signs and severe signs: severe abdominal pain, shock, respiratory distress, coagulation abnormalities, and death.

Dengue patients were classified in Group A - dengue without warning signs, no special condition, no social risk, and no comorbidities; Group B - dengue without warning signs, with special condition, or with social risk and comorbidity; Group C - dengue with warning signs and no severe signs: severe abdominal pain (referred to or on palpation) and continuous, persistent vomiting, fluid accumulation (ascites, pleural effusion, pericardial effusion), postural hypotension and/or lipothymia, hepatomegaly greater than five centimeters, and/or coagulation abnormalities. Group D - dengue with warning signs and severe signs: severe abdominal pain, shock, respiratory distress, coagulation abnormalities, and death.

Dengue patients were classified in Group A - dengue without warning signs, no special condition, no social risk, and no comorbidities; Group B - dengue without warning signs, with special condition, or with social risk and comorbidity; Group C - dengue with warning signs and no severe signs: severe abdominal pain (referred to or on palpation) and continuous, persistent vomiting, fluid accumulation (ascites, pleural effusion, pericardial effusion), postural hypotension and/or lipothymia, hepatomegaly greater than five centimeters, and/or coagulation abnormalities. Group D - dengue with warning signs and severe signs: severe abdominal pain, shock, respiratory distress, coagulation abnormalities, and death.
than 2 cm below the costal margin, mucosal bleeding, lethargy and/or irritability, and progressive increase in hematocrit; Group D - severe dengue: severe plasma extravasation causing shock recognizable by tachycardia, weak and thready pulse, slow capillary refill (>2 seconds), convergent blood pressure (<20 mmHg), tachypnea, oliguria (<1.5 mL/kg/h), hypotension and cyanosis (late stage of shock), accumulation of fluids with respiratory failure, severe bleeding, and severe organ impairment.10

Standard treatment protocol for dengue was followed according to BMH (2016)9, CDC (2015)15 and WHO (2009).16 Classic dengue is characterized by seven-day fever and at least two nonspecific signs and symptoms (headache, malaise, retro-orbital pain, exanthema, myalgia, and arthralgia). Hemorrhagic dengue is characterized by increased vascular permeability leading to bleeding diathesis or disseminated intravascular coagulation, with at least one of the following signs or symptoms: hemorrhagic manifestations, hemoconcentration due to capillary leak, hypoproteinemia, and pleural effusion or ascites. Dengue shock syndrome was considered for all severe cases not fulfilling the hemorrhagic dengue criteria and the classic dengue classification, with one of the following clinical findings: several changes in the nervous system, cardio-respiratory dysfunction, liver failure, thrombocytopenia equal to or less than 20000/mm³, digestive bleeding, pleural effusions, global leukocyte count equal to or less than 1000/m³, suspected case of dengue evolving to death.

The differential diagnosis for Zika and Chikungunya was made by laboratory tests (positive IgM serology and/or positive NS-1). However, only one third of the patients was tested. The KDIGO criteria was used to classify acute renal failure.17

The immunosuppressive drugs taken by patients at the time of dengue presentation included: cyclosporine (CSA), azathioprine (AZA), tacrolimus (TAC), or mycophenolate mofetil (MMF) in combination with low- or high-dose oral steroids.

Leukopenia was defined as leukocyte count below 3500/mm³ and thrombocytopenia was defined as platelet count below 150.000/mm³. Graft dysfunction was defined as an absolute increase in serum creatinine by ≥ 0.5mg/dL.

**Statistical analysis**

All data were entered and analyzed in JASP 0.14.1 (University of Amsterdam). Qualitative variables were expressed in absolute frequencies and percentages. Categorical and continuous data were described as absolute numbers and relative frequencies and as mean and median with standard deviation (SD) and interquartile ranges (IQRs), respectively. The t-test was used for comparison of creatinine before, during, and after hospitalization. A two-sided p < 0.05 was defined as significant.

**Ethical aspects**

The study was approved by the Institutional Ethics committee review board (n° 3.806.077) and was conducted in accordance with the ethical standards established in the 1964 Declaration of Helsinki. Informed consent was obtained from all patients.

**Results**

Nineteen KTR diagnosed with dengue were evaluated. Demographic, hospitalization, and transplant characteristics are described in Table 1. Most patients were admitted 3 days after showing initial symptoms and remained hospitalized for eleven days. The main signs and symptoms were myalgia, headache/retro-orbital pain, and fever (Table 1). Gastrointestinal symptoms were also quite common, mainly manifested by nausea and vomiting, abdominal pain, and diarrhea (Table 1). Two patients presented clinical and ultrasonographic signs consistent with acute cholecystitis without calculus, which improved with resolution of the viral infection. Three patients experienced pleural and/or pericardial effusion and one developed acute myocarditis with thoracic pain and transient elevation of myocardial necrosis markers (Table 1).

According to the risk classification,9 most patients were classified as C group. Two patients required intensive care: one due to diabetic ketoacidosis and the other due to hemorrhagic shock resulting from digestive tract bleeding. None of the patients died or suffered graft loss.

All patients were under a triple immunosuppression regimen and the most common drug combination used was with prednisone, tacrolimus and mycophenolate (Table 1).

Most patients did not receive induction therapy; and there were no differences between the disease severity and the use of different immunosuppression regimens or the intensity of laboratory alterations (Table 1). Temporary suspension or reduction of immunosuppression was required in 58% of patients with leukopenia being the most common reason (Table 2).
Dengue Infection in Kidney Transplant Recipients

| Table 1 | Evolution of creatinine values (mg/dL) during and after the DENV infection in the kidney transplant patients (n = 19). |
|-------------------------|----------------------------------------------------------------------------------------------------------------------------------|
| Age in years (median: max - min) | 43 (17 - 70) |
| Sex                      | Female (n/%) 14/74, Male (n/%) 5/26 |
| Donor type (n/%)         | Living 8/42, Deceased 11/58 |
| Induction (n/%)          | Yes 8/42, No 11/58 |
| Time since transplant (months – mean ± SD) | 72 ± 57.5 |
| ISS at the time of admission for DENV (n/%) | PRED / TAC / MFS 12/63, PRED / TAC / AZA 3/16, PRED / TAC / SRL 3/16, PRED / TAC / EVR 1/5 |
| ISS reduction (n/%)      | Yes 11/58, TAC 1/5, MFS 7/37, AZA 2/11, SRL 1/5, No 8/42 |
| Length of hospital stay in days (mean ± SD) | 11 ± 12 |
| Reason for hospitalization (n/%) | Leukopenia 10/53, Unknown 9/4 |
| Dengue clinical staging according to BMH 20169 (n/%) | Group B 4/21, Group C 13/68, Group D 2/11 |
| PRED: Prednisone, TAC: Tacrolimus, MFS: Mycophenolate sodium, SRL: Sirolimus, AZA: Azathioprine, TG: Thymoglobulin, BSX: Basiliximab, EVR: Everolimus, SD: Standard deviation, BMH 2016: Brazil Ministry of Health9 |

| Table 2 | Laboratorial and clinical characteristics of kidney transplant patients with Dengue (n = 19). |
|--------------------------|------------------------------------------------------------------------------------------------------------------|
| Leukocyte count (mean ± SD; per mm3) | 3,341 ± 1574.8 |
| Lowest leukocyte count | 1,100 |
| Highest leukocyte count | 6,000 |
| Platelet count (mean ± SD; per mm3) | 80,105 ± 59342.5 |
| Lowest platelet count | 16,000 |
| Highest platelet count | 193,000 |
| Hemoglobin count (mean ± SD; g/dL) | 10.9 ± 3.25 |
| Lowest hemoglobin count | 4.8 |
| Highest hemoglobin count | 16.0 |
| Baseline serum creatinine (mean ± SD; mg/dL) | 1.74 ± 0.617 |
| Lowest creatinine | 0.67 |
| Highest creatinine | 2.87 |
| Rise in serum creatinine from baseline (mean ± SD; mg/dL) | 2.45 ± 1.35 |
| Lowest creatinine | 0.98 |
| Highest creatinine | 5.96 |
| Final creatinine (mean ± SD; mg/dL) | 1.71 ± 0.75 |
| Lowest final creatinine | 0.94 |
| Highest final creatinine | 3.80 |
| Clinical features (n/%) | Myalgia 12/63, Headache 9/47, Fever 8/42, Nauseas and vomiting 8/42, Abdominal pain 5/26, Diarrhea 4/21, Hyporexia 4/21, Retro-orbital pain 3/16, Prostration 3/16, Cough 3/16, Digestive bleeding 2/10.5, Chest pain 2/10.5, Dyspnea 2/10.5, Acalculus cholecystitis 2/10.5, Pericardial effusion 2/10.5, Arthralgia 1/5.2, Skin rash 1/5.2, Postural hypotension 1/5.2, Pruritus 1/5.2, Myocarditis 1/5.2, Arterial hypertension 1/5.2, AKI 1/5.2, Coryza 1/5.2 |

Thrombocytopenia was the most frequent laboratorial alteration, appearing in 79.0% of the patients, and 47.3% experienced platelet counts below 50,000/mm³. Leukopenia was also frequent and in 21% of them it was less than 2000/mm³. Two patients had severe anemia and required blood transfusion due to digestive tract hemorrhage (Table 2).

Fifty-eight percent of patients developed AKI, but all recovered renal function (Figure 1). During DENV infection, the mean creatinine was 1.71 mg/dL and rose significantly, reaching levels up to 2.45 mg/dL (p = 0.008) and returning to baseline levels at the end of hospitalization (Cr 1.73 mg/dL; p = 0.80).
Dengue Infection in Kidney Transplant Recipients

DISCUSSION

Dengue fever is a mosquito-borne viral disease that is very common in Latin America, especially in Brazil, where it is endemic and epidemic. Data from the Brazilian Ministry of Health (MS) show that 1,544,987 cases of the disease were reported (735.2 cases/100 thousand population) in 2019. The states of Minas Gerais, São Paulo and Goiás account for 67.9% of the probable cases in the country. The clinical profile in healthy subjects ranges from asymptomatic to nonspecific symptoms such as cephalgia, arthralgia, fever, weakness, myalgia, lower-back pain, retro-orbital pain and malaise to more severe conditions such as leukopenia, thrombocytopenia, bleeding and dysfunction of other organs and systems. KTR living in or who travel to endemic areas have higher risk of acquiring the disease in its varied spectrum of manifestations.

The clinical profile in healthy subjects ranges from asymptomatic to nonspecific symptoms such as cephalgia, arthralgia, fever, weakness, myalgia, lower-back pain, retro-orbital pain and malaise to more severe conditions such as leukopenia, thrombocytopenia, bleeding and dysfunction of other organs and systems. KTR living in or who travel to endemic areas have higher risk of acquiring the disease in its varied spectrum of manifestations.

Most of our patients were receiving PRED, TAC, and MFS for immunosuppression at the time of hospital admission due to dengue, which was similar to what Fernandes et al. (2017) reported. Nasim et al. (2013) used cyclosporine (CSA), azathioprine (AZA) and PRED as ISS in the majority of their patients. Reduction of ISS was necessary in 11 of our patients, especially in those using antiproliferative drugs, due to cytopenia. Fernandes et al. (2017) described the need for temporary reduction or suspension of ISS in their 11 KTR with DENV infection, especially of the drug MIF, also due to cytopenias. According to BMH (2016), most of our patients (68%) had Group C dengue (Table 1).

Regarding laboratory alterations, our patients frequently showed leukopenia and thrombocytopenia, but without an increase of hematocrit, as described in the general population. Some patients already had polycythemia before viral infection, others had anemia mainly due to bleeding. As commented by Nasim et al. (2013), KTR presenting with thrombocytopenia in endemic areas, should be highly suspicion for dengue even if afebrile. They found severe thrombocytopenia in 44% of their patients compared to 60% in the general population reported by Riaz et al. (2009), while there were no cases in the series by Prasad et al. (2012). It seems that KTR have less severe thrombocytopenia. Fernandes et al. (2017) reported thrombocytopenia in most of their cases, with only 33.6% of severe thrombocytopenia. The mean time of thrombocytopenia was 9 days, which is higher than the general population. This fact was also seen by Nasim et al. (2013) with mean thrombocytopenia duration of 11 ± 9 days, compared with 3.6 ± 1.6 days in the general population. Thrombocytopenia with minimum platelet count ranging from 15,300/
Prolonged thrombocytopenia has been observed in transplant recipients with dengue in the general population. Immunocompromised patients might have slow viral clearance causing continued platelet destruction. Studies have suggested that TAC may cause prolonged thrombocytopenia. However, the role of immunosuppressants in thrombocytopenia in transplant recipients with dengue needs further study.

As mentioned earlier, leukopenia occurred frequently in our patients (Table 2), similar as described by Subbiah et al. (2018) and Wiwanitkit (2010). This is due to the cumulative effect of ISS treatment and viral infection. Arun Thomas et al. (2019) showed that leukocyte count was lowest in KTR compared to CKD patients and the control group, probably due to bone marrow suppression by MMF and AZA used for ISS. This might also be another reason why it takes longer time for platelet count to normalize in KTR.

In the present study patients developed mostly common symptoms and signs, often described in the general population, with emphasis on gastrointestinal (nausea, vomiting, abdominal pain, diarrhea, hyporexia) and respiratory manifestation (cough, chest pain, dyspnea). It should be noted that fever was not as prevalent as in the general population, with emphasis on gastrointestinal symptoms such as fever in elderly patients. This might have slow viral clearance causing continued platelet destruction. Studies have suggested that TAC may cause prolonged thrombocytopenia. However, the role of immunosuppressants in thrombocytopenia in transplant recipients with dengue needs further study.

In 2007, Gulati and Maheshwari reported dengue atypical symptoms affecting the nervous, gastrointestinal, cardiac, and renal systems. Two of our KTR developed atypical cholecystitis, characterized by pain in the right hypochondrium, fever, positive Murphy’s sign, altered liver enzymes, and thickening of the gallbladder wall without stones. This is not a common clinical condition in dengue and the pathophysiology is not yet well known. The prolonged fasting, spasm of the duodenal papilla, endotoxemia, microangiopathy, and ischemia-reperfusion injury have been suggested as possible causes of cholestasis and increased viscosity of bile secretion. In dengue hemorrhagic fever, the direct viral entry, increased vascular permeability causing leakage, and serous effusion of protein content could cause thickening of the gallbladder wall. Similarly, cardiac involvement is rare in classic dengue and may manifest as myocarditis and pericarditis, and heart failure, including electrocardiographic changes. In our study, one patient was admitted to the Coronary Care Unit under suspicion of acute myocardial infarction, but viral myocarditis was observed later. Miranda et al. described a series of 81 patients diagnosed with dengue in the general population. The authors found 12 cases positive for at least one cardiac marker and 8 patients had a symptom suggestive of cardiac involvement (acute heart failure, chest pain, and severe hypotension). In 2011, the WHO announced the term “expanded dengue syndrome” (EDS) to refer to cases that do not fall under either dengue hemorrhagic fever or dengue shock syndrome, and have unusual manifestations in other organs such as the cardiovascular, nervous, kidney, intestinal, and the hematologic systems. Currently, reports of under-documented and rare manifestations with severe organ involvement are accumulating. The EDS category helps to establish the diagnosis and prompt treatment of dengue with unusual manifestations.
Previous studies suggested that dengue had a mild impact on KTR, with good recovery, low death risk, and minimal graft function impact. Other publications on KTR with DENV infection report symptoms and signs similar to those in the general population, but with higher occurrence of warning manifestations. According to Renaud et al. (2007) and Azevedo et al. (2007), kidney transplant patients treated with multiple ISS should be less likely to develop the severe form of DENV infection. The latter is thought to occur after secondary infection due to the phenomenon known as antibody dependent enhancement (ADE) response. It could be argued that they are less susceptible because the humoral immune response is suppressed in KTR.

The Subbiah et al. group reported two patients with DENV infection in the post-transplant period that had spontaneous recovery without any complications. However, (2015) and Prasad et al. (2012) showed that DENV infection in the post-transplant period was more serious in their patients, although none died. In agreement with the last two authors, Wiwanitkit (2010) commented that a considerable number of severe cases are reported in KTR.

Weerakkody et al. (2017) compared a total of 168 KTR with the general population, and they have concluded that KTR had significantly less common dengue clinical manifestations such as fever, myalgia, and arthralgia. The authors concluded that the physical and laboratory findings in those patients do not differ from those in the general population and they had significantly more clinical complications and death.

According to Nasim et al. (2013), mortality in their patients occurred mostly in those who had concomitant sepsis, and therefore cannot be attributed to DENV infection alone. The authors suggested that DENV infection should be considered a co-infection that may have contributed to the overall mortality in the study. They described a mild disease with good recovery in the majority of the patients. Only one-quarter of those who developed the severe form of the disease had primary DENV infection and three-quarters had secondary infection, indicating that ISS in KTR does not confer protection against antibody-mediated enhancement seen in secondary infection.

Fernandes et al. (2017) from Brazil described 11 kidney allograft recipients with DENV infection and confirmed the benign nature of the disease in KTR, without mortality. Although 81% of the patients had thrombocytopenia, only 33% had severe thrombocytopenia and the infection tended to follow the usual course of the disease.

In our study, 58% of patients developed AKI, but 100% of them completely recovered renal function (Figure 1). A systematic review of the literature on DENV infection in KTR showed graft dysfunction in almost 60%, in agreement with our study. The authors also found an average creatinine increase of 61.7% during the course of the disease. Mortality was 8.9%, which was higher than that of the normal population (0.062%), but the majority recovered. Nasim et al. (2013) reported that more than half of their patients had graft dysfunction, but most returned to pre-DENV renal function levels within two weeks. Those whose graft function was already significantly compromised before dengue were more likely to have persistent graft dysfunction. They concluded that DENV infection alone does not cause significant graft dysfunction in the absence of other factors in KTR.

All patients of the Subbiah et al. (2018) study recovered normal renal function by the time of recovery from DENV infection. The authors suggested that renal dysfunction is most likely due to the febrile illness, associated dehydration, and other infection-related factors rather than a direct viral cytopathic effect. Similarly, 80% of the patients of the Costa et al. (2015) study in Brazil showed slight worsening during the DENV infection, but returned to basal creatinine levels after infection recovery. Three patients needed RRT, two had graft loss, and one needed dialysis for three weeks and had full recovery of graft function. Azevedo et al. (2007) also showed a transitory dysfunction of the kidney graft during DENV infection. Fernandes et al. (2017) found an increase of mean creatinine from 1.35 to 2.5 mg/dL in the DENV infectious period, which are values very close to those found in our study (Figure 1). The authors informed that the grafts were not damaged at medium or long term and recovery of all patients was satisfactory with mean creatinine of 1.1 mg/dL in the post-infectious period. Probably, this behavior was not due to the direct action of the virus in the kidney parenchyma, but due to factors associated with dehydration/hypovolemia caused by capillary leakage, vomiting, or bleeding. We observed similar kidney function behavior in our patients during the
hospitalization period with significant and transient increase of serum creatinine and return to baseline levels. None of patients progressed to death or graft loss.

This study had some limitations and potential biases. This was a retrospective case series with data collected from medical records. It was not possible to assess the impact on disease morbidity and mortality in these patients because of the lack of serological surveys and routine serological screenings in asymptomatic patients. The strength of our study lies in the fact that the majority of our patients live in endemic DENV regions allowing the recording of their actual clinical evolution. Although this was a retrospective study, our case series stands out because of the severity of the cases. The majority of the patients were classified as a group C and required hospitalization because of the warning signs. Few studies had described such a large number of cases in such a short period of time, a total of nineteen cases in only six months. In addition, we reported two cases with acute acalculous cholecystitis and myocarditis (Table 2).

**CONCLUSIONS**

Dengue is a human viral mosquito-borne infection very important worldwide, which should be included in the differential diagnosis of KTR with fever. According with our results, dengue in KTR seems to have a course similar to the general population, although we did not have a control group. Some conclusions were not possible from these data given the lack of a comparable group and lack of comparison for the ISS and type of donor factors. Therefore, we conclude that the immunosuppression, preexisting kidney disease, or type of donor did not define the outcome in most patients.

We believe that special attention should be paid to patients whose signs and symptoms differ from those of classic DENV fever, as they may develop severe organic commitment, resulting in acute graft dysfunction. The main clinical signs and symptoms in our patients were myalgia, headache, fever, nausea and vomiting, abdominal pain, diarrhea, and hyporexia. Compared with the general population, the frequency of signs and symptoms was quite similar, with the exception of arthralgia and retro-orbital pain, which were less common. Laboratory findings were leukopenia, thrombocytopenia and anemia, which are commonly associated with DENV infection. No patient experienced death or graft loss, with renal function improving at the end of hospitalization.

**ACKNOWLEDGMENTS**

We thank all patients for their participation in our study and our colleagues for their valuable clinical patient support.

**AUTHORS’ CONTRIBUTION**

CR, SADT, SMCM, PAMS and MGMGP were responsible for the research idea and study design. CR, SADT, SMCM were responsible for data acquisition. CR, PAMS, SMCM and MGMGP were responsible for supervision or mentorship.

**CONFLICT OF INTEREST**

There are no conflicts of interest between the investigators and the patients, who authorized by signing the free and informed consent form.

**REFERENCES**

1. Humayoun MA, Waseem T, Jawa AA, Hashmi MS, Akram J. Multiple dengue serotypes and high frequency of dengue hemorrhagic fever at two tertiary care hospitals in Lahore during the 2008 dengue virus outbreak in Punjab, Pakistan. Int J Infect Dis. 2010 Sep;14(Suppl 3):e54-e59.
2. Nasim A, Anis S, Baqi S, Akhtar SF, Baig-Ansari N. Clinical presentation and outcome of dengue in live-related renal transplant recipients in Karachi, Pakistan. Transpl Infect Dis. 2013 Oct;15(5):516-25.
3. Costa SD, Silva Junior GB, Jacinto CN, Martiniano LVM, Amaral YS, Paes FJVN, et al. Dengue fever among renal transplant recipients: a series of 10 cases in a tropical country. Am Trop Med Hyg. 2015;93(2):394-36.
4. Hales S, Wet ND, Maindonald J, Woodward A. Potential effect of population and climate changes on global distribution of dengue fever: an empirical model. Lancet. 2002;360(9336):830-4.
5. Thomas ETA, George J, Sruthi D, Vineetha NS, Gracious N. Clinical course of dengue fever and its impact on renal function in renal transplant recipients and patients with chronic kidney disease. Nephrology (Carlton). 2019 May;24(5):564-8.
6. World Health Organization (WHO). Special Programme for Research, Training in Tropical Diseases. Department of Control of Neglected Tropical Diseases - Epidemic & Pandemic Alert. Dengue: comprehensive guidelines for prevention and control of dengue and dengue haemorrhagic fever. Geneva: WHO; 2018.
7. Weerakkody RM, Patrick JA, Sheriff MH. Dengue fever in renal transplant patients: a systematic review of literature. BMC Nephrol. 2017 Jan;18:15. DOI: https://doi.org/10.1186/s12882-016-0428-y
8. Ministério da Saúde (BR). Ministério da Saúde lança campanha de combate ao Aedes aegypti [Internet]. Brasília (DF): Agência Brasil; 2016; [acesso em 2021 Mar 05]. Available from: https://agenciabrasil.ebc.com.br/saude/noticia/2020-11/ministerio-da-saude-lanca-campanha-de-combate-ao-aedes-aegypti
9. Ministério da Saúde (BR). Dengue: diagnóstico e manejo clínico adulto e criança [Internet]. 5ª ed. Brasília (DF): Ministério da Saúde; 2016; [acesso em 2021 Mar 05]. Available from: https://portalarquivos2.saude.gov.br/images/pdf/2016/janeiro/14/dengue-manejo-adulto-crianca-5d.pdf
10. World Health Organization (WHO). Dengue: guidelines for diagnosis, treatment, prevention and control [Internet]. Geneva: WHO; 2009; [acesso em 2021 Mar 05]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK143157/

11. Tan FL, Loh DL, Prabhakaran K, Tambyah PA, Yap HK. Dengue haemorrhagic fever after living donor renal transplantation. Nephrol Dial Transplant. 2005 Feb;20(2):447-8.

12. Prasad N, Bhadauria D, Sharma RK, Gupta A, Kaul A, Srivastava A. Dengue virus infection in renal allograft recipients: a case series during 2010 outbreak. Transpl Infect Dis. 2012;14(2):163-8.

13. Associação Brasileira de Transplantes de Órgãos (ABTO). Dimensionamento dos transplantes no Brasil e em casa estado. Registo Brasileiro de Transplantes (RBT) [Internet]. 2019; [citado 2021 Mar 05]; XXI(4):9. Available from: http://www.abto.org.br/abtov03/Upload/file/RBT/2019/RBT-2019-leitura.pdf

14. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009 May;150(9):604-12.

15. Subbiah A, Bagchi S, Bhowmik D, Mahajan S, Yadav RK, Chhabra Y, et al. Dengue fever in renal allograft recipients: clinical course and outcome. Transpl Infect Dis. 2018 Mar;20(3):e12875. DOI: https://doi.org/10.1111/tid.12875

16. Center for Disease Control and Prevention (CDC). Dengue virus infections. 2015 case definition [Internet]. Atlanta: CDC; 2015; [acesso em 2021 Mar 5]. Available from: https://www.cdc.gov/mndss/conditions/dengue-virus-infections/case-definition/2015/

17. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO Clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2(1):1-150. DOI: https://doi.org/10.1038/ksuip.2012.1

18. Ministério da Saúde (BR). Secretaria de Vigilância em Saúde. Boletim Epidemiológico. Monitoramento dos casos de arboviroses urbanas transmitidas pelo Aedes (dengue, chikungunya e Zika) [Internet]. Brasília (DF): Ministério da Saúde; 2020; [acesso em 2021 Abr 13]. Available from: http://plataforma.saude.gov.br/anomalias-congenitas/boletim-epidemiologico-SVS-05-2020.pdf

19. Fernandes FPCBC, Siqueira RA, Girão ES, Siqueira RA, Mota MU, Marques LCBE, et al. Dengue in renal transplant recipients: Clinical course and impact on renal function. World J Transplant. 2017 Feb;7(1):57-63.

20. Riaz MM, Mumtaz K, Khan MS, Patel J, Tariq M, Hilal H, et al. Outbreak of dengue fever in Karachi 2006: a clinical perspective. J Pak Med Assoc. 2009 Jun;59(6):439-44.

21. Tai DY, Chee YC, Chan KW. The natural history of dengue illness based on a study of hospitalized patients in Singapore. Singapore Med J. 1999 Apr;40(4):238-42.

22. Renaud CJ, Manjit K, Pary S. Dengue has a benign presentation in renal transplant patients: a case series. Nephrology (Carlton). 2007 Jun;12(3):305-7.

23. Wiwankirikit V. Dengue infection in kidney transplant patients: an appraisal on clinical manifestation. Iran J Kidney Dis. 2010 Apr;4(2):168.

24. Azvedo LS, Carvalho DBM, Matuck T, Alvarenga MF, Morgado L, Magalhães I, et al. Dengue in renal transplant patients: a retrospective analysis. Transplantation. 2007 Sep;84(6):792-4.

25. Tangnaran Chatikat K, Tirapanch W, Tapanay-Olarn W, Sumethkul V, Sirachainan N, Watcharanan S, et al. Severe nonfebrile dengue infection in an adolescent after postoperative kidney transplantation: a case report. Transplant Proc. 2012 Jan;44(1):303-6.

26. Opal SM, Girard TD, Ely EW. The immunopathogenesis of sepsis in elderly patients. Clin Infect Dis. 2005 Nov;41(Suppl 7):S504-S12.

27. Low JGH, Ong A, Tan LK, Chaterji S, Chow A, Lim WY, et al. The early clinical features of dengue in adults: challenges for early clinical diagnosis. PLoS Negl Trop Dis. 2011 May;5(5):e1191.

28. Teixeira MG, Barreto ML, Costa MC, Ferreira LD, Vasconcelos PF, Cairncross S. Dynamics of dengue virus circulation: a silent epidemic in a complex urban area. Trop Med Int Health. 2002;7(9):757-62.

29. Gulati S, Maheshwari A. Atypical manifestations of dengue. Trop Med Int Health. 2007 Sep;12(9):1087-95.

30. Osorio J, Carvaljal C, Sussman O, Buitrago R, Franco-Paredes C. Acute liver failure due to dengue virus infection. Int J Infect Dis. 2008 Jul;12(4):444-5.

31. Ramanathan K, Teo L, Raymond WCC, MacLaren G. Dengue myopericarditis mimicking acute myocardial infarction. Circulation. 2013;113(23):e319-22.

32. Miranda CH, Borges MC, Matsuno AK, Vilar FC, Gali LG, Boongird S, Bruminhent J. Epidemiology and outcomes of dengue viral infection. Clin Infect Dis. 2013 Sep;57(6):812-9.

33. Umakanth M, Suganthan N. Unusual manifestations of dengue fever: a review on expanded dengue syndrome. Cureus. 2020 Jul;12(4):e10678.

34. Pinsai S, Kiertiburanakul S, Watcharanan SP, Kantachuvessiri S, Boongird S, Bruminhent J. Epidemiology and outcomes of dengue in kidney transplant recipients: a 20-year retrospective analysis and comparative literature review. Clin Transplant. 2019 Jan;33(1):e13458.

35. Farrar J, Focks D, Gubler D, Barrera R, Guzman MG, Simmons C, et al. Towards a global dengue research agenda. Trop Med Int Health. 2007 Jun;12(6):695-9.